Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly summarizes the high response rate seen in patients with mantle cell lymphoma (MCL) following treatment with a combination of acalabrutinib plus venetoclax and rituximab. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

свернуть